{"id":32468,"date":"2022-12-11T10:00:24","date_gmt":"2022-12-11T05:00:24","guid":{"rendered":"http:\/\/myanmarnewsgazette.com\/?guid=1eedcdc3189e6fc4a92450b71e3b8249"},"modified":"2022-12-11T10:00:24","modified_gmt":"2022-12-11T05:00:24","slug":"junshi-biosciences-announces-updated-clinical-data-from-phase-i-study-of-anti-btla-antibody-tifcemalimab-in-treatment-of-relapsed-refractory-lymphomas-at-64th-ash-annual-meeting-2","status":"publish","type":"post","link":"https:\/\/myanmarnewsgazette.com\/junshi-biosciences-announces-updated-clinical-data-from-phase-i-study-of-anti-btla-antibody-tifcemalimab-in-treatment-of-relapsed-refractory-lymphomas-at-64th-ash-annual-meeting-2\/","title":{"rendered":"Junshi Biosciences Announces Updated Clinical data from Phase I study of anti-BTLA antibody Tifcemalimab in Treatment of Relapsed\/Refractory Lymphomas at 64th ASH Annual Meeting"},"content":{"rendered":"
\n

— Preliminary study results show that tifcemalimab is well-tolerated at all administered doses. The observed clinical activity of tifcemalimab in combination with toripalimab in lymphoma patients refractory to checkpoint inhibitors warrants further evaluation. Combination dose expansion is under way. <\/em><\/p>\n

— Among the 28 evaluable patients who received the combination regimen, while 85.7% of the patients progressed upon prior anti-PD-1, 39.3% achieved ORR, and median DoR has not yet been reached.<\/em><\/p>\n

SHANGHAI, China, Dec. 10, 2022 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences\u201d, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the updated preliminary data from a Phase I study of tifcemalimab as a single agent or in combination with toripalimab in relapsed\/refractory lymphomas in a poster at the 64th<\/sup> American Society of Hematology (ASH) Annual Meeting. Tifcemalimab is the world\u2019s first-in-human anti-tumor anti-BTLA monoclonal antibody independently developed by the company.<\/p>\n

\u201cNowadays, PD-1 inhibitors are widely used in the treatment of lymphomas, particularly relapsed or refractory classical Hodgkin\u2019s lymphoma (R\/R cHL),\u201d said Dr. Yuqin Song of Peking University Cancer Hospital and Institute. \u201cHowever, if PD-1 inhibitors fail, there is no standard treatment to resort to, thus new treatment methods are urgently needed in clinical practice. Through research, we have discovered that these types of patients can expect to benefit once again when treated with tifcemalimab and toripalimab combined. We\u2019ve also observed a similar advantage in this treatment method as well as other immune checkpoint inhibitors\u2014both may bring long-term survival benefits to patients. As the clinical trials continue, we look forward to observing tifcemalimab\u2019s performance and the new treatment options it can bring to more lymphoma patients.\u201d<\/p>\n

\u201cThe first of its kind in the entire world, tifcemalimab exhibits promising safety and efficacy in early clinical trials,\u201d said Dr. Jianjun Zou, Global Research and Development President at Junshi Biosciences. \u201cIn particular, the updated research data released at the ASH Annual Meeting highlights that the tifcemalimab-toripalimab dual immunotherapy is promising for patients with relapsed\/refractory lymphoma resistant to anti-PD-1 monoclonal antibodies, and is worth further evaluation. Apart from that, we\u2019ve also seen its outstanding safety and efficacy in patients with solid tumors, and are eager for further verification in subsequent research.\u201d<\/p>\n

The study is a single-arm, open-label, multicenter, dose-escalation phase I study (NCT0447772) evaluating the safety and efficacy of tifcemalimab as a single agent or in combination with toripalimab in relapsed\/refractory lymphomas. This is the very first time an anti-BTLA antibody was evaluated for safety and efficacy in the treatment of lymphomas. Earlier this year in June, tifcemalimab made its debut with preliminary data from the clinical trials at the American Society of Clinical Oncology (ASCO) annual meeting, creating a milestone for all BTLA-targeting drugs in the field of cancer. Now, updated results from the clinical trial for lymphomas have been presented at the ASH annual meeting. The leading PI of this study include Dr. Jun Ma from Harbin Institute of Hematology and Oncology and Dr. Jun Zhu from Peking University Cancer Hospital and Institute, with Dr. Yuqin Song as the presenting author.<\/p>\n

By the cutoff date of October 26, 2022, a total of 63 patients with relapsed\/refractory lymphoma were enrolled in the study, including 43 patients with Hodgkin’s lymphoma (HL) and 20 with non-Hodgkin’s lymphoma (NHL). Among the 25 evaluable patients who received monotherapy, 9 received monotherapy dose escalation and 16 received monotherapy dose expansion; among the 38 patients who received combination treatment, 6 received combination dose escalation and 32 received combination dose expansion. Patients were heavily treated with median 4 prior lines of therapy. 46 patients (73.0%) received prior anti-PD-1\/L1 therapy.<\/p>\n

In terms of safety and tolerability, as of October 26, 2022, no dose-limiting toxicity (DLT) was observed in either monotherapy or combination dose escalation. Additionally, the immune related adverse event (irAE) profile of the combination was consistent with toripalimab monotherapy, and no novel safety signals were identified in the combination cohorts.<\/p>\n

Regarding clinical anti-tumor\u00a0activity, as of October 26, 2022, the median follow-up was 29.1 weeks, 1 case of partial remission (PR) and 7 cases of stable disease (SD) were observed among the 25 evaluable patients receiving monotherapy. Among the 28 evaluable patients receiving the combination regimen, 24 (85.7%) patients progressed upon prior anti-PD-1, and 1 complete response (CR), 10 PR, and 13 SD were observed. The objective response rate (ORR) reached 39.3% and the disease control rate (DCR) reached 85.7%. All patients with CR\/PR responses in the combination groups are ongoing by the cutoff date and the median duration of response (DoR) is not yet reached.<\/p>\n

About Tifcemalimab (JS004\/TAB004)<\/strong>
\nTifcemalimab is the world\u2019s first-in-human recombinant humanized anti-BTLA (B- and T-lymphocyte attenuator) monoclonal antibody independently developed by Junshi Biosciences. So far, tifcemalimab has entered phase Ib\/II study, and several trials of tifcemalimab in combination with toripalimab in patients with different types of tumors are ongoing in China and the United States.<\/p>\n

In 2003, B and T lymphocyte attenuator (BTLA), the target of tifcemalimab was discovered. It is a member of the CD28 receptor family. It has a single IgSF V extracellular domain; its sequence is similar to other molecules of the CD28 family (such as PD-1 and CTLA-4).<\/p>\n

BTLA is expressed in the T lymphocyte, B lymphocyte and dendritic cell subpopulations. In 2005, the interaction between BTLA and its ligand, Herpes virus entry mediator (HVEM) was discovered. HVEM is a TNF receptor extensively expressed in the hematopoietic system and is confirmed as the ligand of BTLA.<\/p>\n

BTLA is an immunoglobulin associated membrane protein; its protein structure is similar to that of the transmembrane receptors (CTLA-4 and PD-1). Under normal physiological conditions, after BTLA binds with its ligand HVEM, the over-activation of lymphocytes in the human body is inhibited, thus avoiding autoimmune injuries.<\/p>\n

By binding with BTLA, tifcemalimab blocks the HVEM-BTLA interaction, thereby obstructing the BTLA-mediated inhibitory signal pathways and activating the tumor specific lymphocytes.<\/p>\n

Tifcemalimab interferes with the HVEM-BTLA interaction by binding to BTLA, thus blocking the inhibitory signal pathway mediated by BTLA and resulting in the activation of tumor-specific lymphocytes.<\/p>\n

About Junshi Biosciences<\/strong>
\nFounded in December 2012, Junshi Biosciences (HKEX: 1877; SSE: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutics. The company has established a diversified R&D pipeline comprising over 50 drug candidates, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China. Its first-in-human anti-BTLA monoclonal antibody for the treatment of various cancers was the first in the world to be approved for clinical trials by the FDA and NMPA and has since entered Phase Ib\/II trials in both China and the US. Its anti-PCSK9 monoclonal antibody was the first in\u00a0China\u00a0to be approved for clinical trials by the NMPA.<\/p>\n

In the face of the pandemic, Junshi Biosciences\u2019 response was strong and immediate, joining forces with Chinese and international scientific research institutions and enterprises to develop an arsenal of drug candidates to combat COVID-19, taking the initiative to shoulder the social responsibility of Chinese pharmaceutical companies by prioritizing and accelerating COVID-19 R&D. Among the many drug candidates is JS016 (etesevimab), China\u2019s first neutralizing fully human monoclonal antibody against SARS-CoV-2 and the result of the combined efforts of Junshi Biosciences, the\u00a0Institute of Microbiology of the Chinese Academy\u00a0of Science and Lilly. JS016 administered with bamlanivimab has been granted Emergency Use Authorizations (EUA) in over 15 countries and regions worldwide. Meanwhile, VV116, a new oral nucleoside analog anti-SARS-CoV-2 drug designed to hinder virus replication, is in global Phase III clinical trials. The JS016 and VV116 programs are a part of the company\u2019s continuous innovation for disease control and prevention of the global pandemic.<\/p>\n

Junshi Biosciences has more than 3,100 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing and Guangzhou). For more information, please visit: http:\/\/junshipharma.com<\/a>.<\/p>\n

Junshi Biosciences Contact Information<\/strong>
\nIR Team:
\nJunshi Biosciences
\ninfo@junshipharma.com<\/a>
\n+ 86 021-6105 8800<\/p>\n

PR Team:
\nJunshi Biosciences
\nZhi Li
\nzhi_li@junshipharma.com<\/a>
\n+ 86 021-6105 8800<\/p>\n

GlobeNewswire Distribution ID 8712127<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

\u2014 Preliminary study results show that tifcemalimab is well-tolerated at all administered doses. The observed clinical activity of tifcemalimab in combination with toripalimab in lymphoma patients refractory to checkpoint inhibitors warrants further evaluation. Combination dose expansion is under way. \u2014 Among the 28 evaluable patients who received the combination regimen, while 85.7% of the patients [\u2026]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[14],"tags":[],"yoast_head":"\nJunshi Biosciences Announces Updated Clinical data from Phase I study of anti-BTLA antibody Tifcemalimab in Treatment of Relapsed\/Refractory Lymphomas at 64th ASH Annual Meeting - Myanmar News Gazette<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/myanmarnewsgazette.com\/junshi-biosciences-announces-updated-clinical-data-from-phase-i-study-of-anti-btla-antibody-tifcemalimab-in-treatment-of-relapsed-refractory-lymphomas-at-64th-ash-annual-meeting-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Junshi Biosciences Announces Updated Clinical data from Phase I study of anti-BTLA antibody Tifcemalimab in Treatment of Relapsed\/Refractory Lymphomas at 64th ASH Annual Meeting - Myanmar News Gazette\" \/>\n<meta property=\"og:description\" content=\"\u2014 Preliminary study results show that tifcemalimab is well-tolerated at all administered doses. The observed clinical activity of tifcemalimab in combination with toripalimab in lymphoma patients refractory to checkpoint inhibitors warrants further evaluation. Combination dose expansion is under way. \u2014 Among the 28 evaluable patients who received the combination regimen, while 85.7% of the patients [\u2026]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/myanmarnewsgazette.com\/junshi-biosciences-announces-updated-clinical-data-from-phase-i-study-of-anti-btla-antibody-tifcemalimab-in-treatment-of-relapsed-refractory-lymphomas-at-64th-ash-annual-meeting-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Myanmar News Gazette\" \/>\n<meta property=\"article:published_time\" content=\"2022-12-11T05:00:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ci6.googleusercontent.com\/proxy\/Bse3_g6hNtgUPf1Gv7sPn2rL3xfKl2kuIL4yCLlrgSYQldSibo1k-_IQf8wTG2Fm6Tgm1_iMxetzdWRwSVLSUsa813tF9-RIRbIhb21y2K4eQJ7e342nKKyOYsbD56Ct0kvCmVQL7WRbSeTP7rPLimhpWmFbZ9Hi5usaZxrko1vxlXF55dRuSiRH44TNaA=s0-d-e1-ft#https:\/\/ml.globenewswire.com\/media\/YjYzY2RiOTAtYjViZC00ODEyLWE4ZjktOTBmMzIzODM5N2YxLTEyMDY5Mjg=\/tiny\/Junshi-Biosciences.png\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/myanmarnewsgazette.com\/junshi-biosciences-announces-updated-clinical-data-from-phase-i-study-of-anti-btla-antibody-tifcemalimab-in-treatment-of-relapsed-refractory-lymphomas-at-64th-ash-annual-meeting-2\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/myanmarnewsgazette.com\/junshi-biosciences-announces-updated-clinical-data-from-phase-i-study-of-anti-btla-antibody-tifcemalimab-in-treatment-of-relapsed-refractory-lymphomas-at-64th-ash-annual-meeting-2\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/myanmarnewsgazette.com\/#\/schema\/person\/c7e2b10e6a2fda5bcbb164cc7b208a0f\"},\"headline\":\"Junshi Biosciences Announces Updated Clinical data from Phase I study of anti-BTLA antibody Tifcemalimab in Treatment of Relapsed\/Refractory Lymphomas at 64th ASH Annual Meeting\",\"datePublished\":\"2022-12-11T05:00:24+00:00\",\"dateModified\":\"2022-12-11T05:00:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/myanmarnewsgazette.com\/junshi-biosciences-announces-updated-clinical-data-from-phase-i-study-of-anti-btla-antibody-tifcemalimab-in-treatment-of-relapsed-refractory-lymphomas-at-64th-ash-annual-meeting-2\/\"},\"wordCount\":1347,\"publisher\":{\"@id\":\"https:\/\/myanmarnewsgazette.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/myanmarnewsgazette.com\/junshi-biosciences-announces-updated-clinical-data-from-phase-i-study-of-anti-btla-antibody-tifcemalimab-in-treatment-of-relapsed-refractory-lymphomas-at-64th-ash-annual-meeting-2\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ci6.googleusercontent.com\/proxy\/Bse3_g6hNtgUPf1Gv7sPn2rL3xfKl2kuIL4yCLlrgSYQldSibo1k-_IQf8wTG2Fm6Tgm1_iMxetzdWRwSVLSUsa813tF9-RIRbIhb21y2K4eQJ7e342nKKyOYsbD56Ct0kvCmVQL7WRbSeTP7rPLimhpWmFbZ9Hi5usaZxrko1vxlXF55dRuSiRH44TNaA=s0-d-e1-ft#https:\/\/ml.globenewswire.com\/media\/YjYzY2RiOTAtYjViZC00ODEyLWE4ZjktOTBmMzIzODM5N2YxLTEyMDY5Mjg=\/tiny\/Junshi-Biosciences.png\",\"articleSection\":[\"Press Releases\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/myanmarnewsgazette.com\/junshi-biosciences-announces-updated-clinical-data-from-phase-i-study-of-anti-btla-antibody-tifcemalimab-in-treatment-of-relapsed-refractory-lymphomas-at-64th-ash-annual-meeting-2\/\",\"url\":\"https:\/\/myanmarnewsgazette.com\/junshi-biosciences-announces-updated-clinical-data-from-phase-i-study-of-anti-btla-antibody-tifcemalimab-in-treatment-of-relapsed-refractory-lymphomas-at-64th-ash-annual-meeting-2\/\",\"name\":\"Junshi Biosciences Announces Updated Clinical data from Phase I study of anti-BTLA antibody Tifcemalimab in Treatment of Relapsed\/Refractory Lymphomas at 64th ASH Annual Meeting - Myanmar News Gazette\",\"isPartOf\":{\"@id\":\"https:\/\/myanmarnewsgazette.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/myanmarnewsgazette.com\/junshi-biosciences-announces-updated-clinical-data-from-phase-i-study-of-anti-btla-antibody-tifcemalimab-in-treatment-of-relapsed-refractory-lymphomas-at-64th-ash-annual-meeting-2\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/myanmarnewsgazette.com\/junshi-biosciences-announces-updated-clinical-data-from-phase-i-study-of-anti-btla-antibody-tifcemalimab-in-treatment-of-relapsed-refractory-lymphomas-at-64th-ash-annual-meeting-2\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ci6.googleusercontent.com\/proxy\/Bse3_g6hNtgUPf1Gv7sPn2rL3xfKl2kuIL4yCLlrgSYQldSibo1k-_IQf8wTG2Fm6Tgm1_iMxetzdWRwSVLSUsa813tF9-RIRbIhb21y2K4eQJ7e342nKKyOYsbD56Ct0kvCmVQL7WRbSeTP7rPLimhpWmFbZ9Hi5usaZxrko1vxlXF55dRuSiRH44TNaA=s0-d-e1-ft#https:\/\/ml.globenewswire.com\/media\/YjYzY2RiOTAtYjViZC00ODEyLWE4ZjktOTBmMzIzODM5N2YxLTEyMDY5Mjg=\/tiny\/Junshi-Biosciences.png\",\"datePublished\":\"2022-12-11T05:00:24+00:00\",\"dateModified\":\"2022-12-11T05:00:24+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/myanmarnewsgazette.com\/junshi-biosciences-announces-updated-clinical-data-from-phase-i-study-of-anti-btla-antibody-tifcemalimab-in-treatment-of-relapsed-refractory-lymphomas-at-64th-ash-annual-meeting-2\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/myanmarnewsgazette.com\/junshi-biosciences-announces-updated-clinical-data-from-phase-i-study-of-anti-btla-antibody-tifcemalimab-in-treatment-of-relapsed-refractory-lymphomas-at-64th-ash-annual-meeting-2\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/myanmarnewsgazette.com\/junshi-biosciences-announces-updated-clinical-data-from-phase-i-study-of-anti-btla-antibody-tifcemalimab-in-treatment-of-relapsed-refractory-lymphomas-at-64th-ash-annual-meeting-2\/#primaryimage\",\"url\":\"https:\/\/ci6.googleusercontent.com\/proxy\/Bse3_g6hNtgUPf1Gv7sPn2rL3xfKl2kuIL4yCLlrgSYQldSibo1k-_IQf8wTG2Fm6Tgm1_iMxetzdWRwSVLSUsa813tF9-RIRbIhb21y2K4eQJ7e342nKKyOYsbD56Ct0kvCmVQL7WRbSeTP7rPLimhpWmFbZ9Hi5usaZxrko1vxlXF55dRuSiRH44TNaA=s0-d-e1-ft#https:\/\/ml.globenewswire.com\/media\/YjYzY2RiOTAtYjViZC00ODEyLWE4ZjktOTBmMzIzODM5N2YxLTEyMDY5Mjg=\/tiny\/Junshi-Biosciences.png\",\"contentUrl\":\"https:\/\/ci6.googleusercontent.com\/proxy\/Bse3_g6hNtgUPf1Gv7sPn2rL3xfKl2kuIL4yCLlrgSYQldSibo1k-_IQf8wTG2Fm6Tgm1_iMxetzdWRwSVLSUsa813tF9-RIRbIhb21y2K4eQJ7e342nKKyOYsbD56Ct0kvCmVQL7WRbSeTP7rPLimhpWmFbZ9Hi5usaZxrko1vxlXF55dRuSiRH44TNaA=s0-d-e1-ft#https:\/\/ml.globenewswire.com\/media\/YjYzY2RiOTAtYjViZC00ODEyLWE4ZjktOTBmMzIzODM5N2YxLTEyMDY5Mjg=\/tiny\/Junshi-Biosciences.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/myanmarnewsgazette.com\/junshi-biosciences-announces-updated-clinical-data-from-phase-i-study-of-anti-btla-antibody-tifcemalimab-in-treatment-of-relapsed-refractory-lymphomas-at-64th-ash-annual-meeting-2\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/myanmarnewsgazette.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Junshi Biosciences Announces Updated Clinical data from Phase I study of anti-BTLA antibody Tifcemalimab in Treatment of Relapsed\/Refractory Lymphomas at 64th ASH Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/myanmarnewsgazette.com\/#website\",\"url\":\"https:\/\/myanmarnewsgazette.com\/\",\"name\":\"Myanmar News Gazette\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/myanmarnewsgazette.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/myanmarnewsgazette.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/myanmarnewsgazette.com\/#organization\",\"name\":\"Myanmar News Gazette\",\"url\":\"https:\/\/myanmarnewsgazette.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/myanmarnewsgazette.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/myanmarnewsgazette.com\/wp-content\/uploads\/2022\/07\/Myanmar-logo.png\",\"contentUrl\":\"https:\/\/myanmarnewsgazette.com\/wp-content\/uploads\/2022\/07\/Myanmar-logo.png\",\"width\":200,\"height\":200,\"caption\":\"Myanmar News Gazette\"},\"image\":{\"@id\":\"https:\/\/myanmarnewsgazette.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/myanmarnewsgazette.com\/#\/schema\/person\/c7e2b10e6a2fda5bcbb164cc7b208a0f\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/myanmarnewsgazette.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/ff4aa10d4f36ab9dc3cce9e101792273?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/ff4aa10d4f36ab9dc3cce9e101792273?s=96&d=mm&r=g\",\"caption\":\"admin\"},\"url\":\"https:\/\/myanmarnewsgazette.com\/author\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Junshi Biosciences Announces Updated Clinical data from Phase I study of anti-BTLA antibody Tifcemalimab in Treatment of Relapsed\/Refractory Lymphomas at 64th ASH Annual Meeting - Myanmar News Gazette","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/myanmarnewsgazette.com\/junshi-biosciences-announces-updated-clinical-data-from-phase-i-study-of-anti-btla-antibody-tifcemalimab-in-treatment-of-relapsed-refractory-lymphomas-at-64th-ash-annual-meeting-2\/","og_locale":"en_US","og_type":"article","og_title":"Junshi Biosciences Announces Updated Clinical data from Phase I study of anti-BTLA antibody Tifcemalimab in Treatment of Relapsed\/Refractory Lymphomas at 64th ASH Annual Meeting - Myanmar News Gazette","og_description":"\u2014 Preliminary study results show that tifcemalimab is well-tolerated at all administered doses. The observed clinical activity of tifcemalimab in combination with toripalimab in lymphoma patients refractory to checkpoint inhibitors warrants further evaluation. Combination dose expansion is under way. \u2014 Among the 28 evaluable patients who received the combination regimen, while 85.7% of the patients [\u2026]","og_url":"https:\/\/myanmarnewsgazette.com\/junshi-biosciences-announces-updated-clinical-data-from-phase-i-study-of-anti-btla-antibody-tifcemalimab-in-treatment-of-relapsed-refractory-lymphomas-at-64th-ash-annual-meeting-2\/","og_site_name":"Myanmar News Gazette","article_published_time":"2022-12-11T05:00:24+00:00","og_image":[{"url":"https:\/\/ci6.googleusercontent.com\/proxy\/Bse3_g6hNtgUPf1Gv7sPn2rL3xfKl2kuIL4yCLlrgSYQldSibo1k-_IQf8wTG2Fm6Tgm1_iMxetzdWRwSVLSUsa813tF9-RIRbIhb21y2K4eQJ7e342nKKyOYsbD56Ct0kvCmVQL7WRbSeTP7rPLimhpWmFbZ9Hi5usaZxrko1vxlXF55dRuSiRH44TNaA=s0-d-e1-ft#https:\/\/ml.globenewswire.com\/media\/YjYzY2RiOTAtYjViZC00ODEyLWE4ZjktOTBmMzIzODM5N2YxLTEyMDY5Mjg=\/tiny\/Junshi-Biosciences.png"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/myanmarnewsgazette.com\/junshi-biosciences-announces-updated-clinical-data-from-phase-i-study-of-anti-btla-antibody-tifcemalimab-in-treatment-of-relapsed-refractory-lymphomas-at-64th-ash-annual-meeting-2\/#article","isPartOf":{"@id":"https:\/\/myanmarnewsgazette.com\/junshi-biosciences-announces-updated-clinical-data-from-phase-i-study-of-anti-btla-antibody-tifcemalimab-in-treatment-of-relapsed-refractory-lymphomas-at-64th-ash-annual-meeting-2\/"},"author":{"name":"admin","@id":"https:\/\/myanmarnewsgazette.com\/#\/schema\/person\/c7e2b10e6a2fda5bcbb164cc7b208a0f"},"headline":"Junshi Biosciences Announces Updated Clinical data from Phase I study of anti-BTLA antibody Tifcemalimab in Treatment of Relapsed\/Refractory Lymphomas at 64th ASH Annual Meeting","datePublished":"2022-12-11T05:00:24+00:00","dateModified":"2022-12-11T05:00:24+00:00","mainEntityOfPage":{"@id":"https:\/\/myanmarnewsgazette.com\/junshi-biosciences-announces-updated-clinical-data-from-phase-i-study-of-anti-btla-antibody-tifcemalimab-in-treatment-of-relapsed-refractory-lymphomas-at-64th-ash-annual-meeting-2\/"},"wordCount":1347,"publisher":{"@id":"https:\/\/myanmarnewsgazette.com\/#organization"},"image":{"@id":"https:\/\/myanmarnewsgazette.com\/junshi-biosciences-announces-updated-clinical-data-from-phase-i-study-of-anti-btla-antibody-tifcemalimab-in-treatment-of-relapsed-refractory-lymphomas-at-64th-ash-annual-meeting-2\/#primaryimage"},"thumbnailUrl":"https:\/\/ci6.googleusercontent.com\/proxy\/Bse3_g6hNtgUPf1Gv7sPn2rL3xfKl2kuIL4yCLlrgSYQldSibo1k-_IQf8wTG2Fm6Tgm1_iMxetzdWRwSVLSUsa813tF9-RIRbIhb21y2K4eQJ7e342nKKyOYsbD56Ct0kvCmVQL7WRbSeTP7rPLimhpWmFbZ9Hi5usaZxrko1vxlXF55dRuSiRH44TNaA=s0-d-e1-ft#https:\/\/ml.globenewswire.com\/media\/YjYzY2RiOTAtYjViZC00ODEyLWE4ZjktOTBmMzIzODM5N2YxLTEyMDY5Mjg=\/tiny\/Junshi-Biosciences.png","articleSection":["Press Releases"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/myanmarnewsgazette.com\/junshi-biosciences-announces-updated-clinical-data-from-phase-i-study-of-anti-btla-antibody-tifcemalimab-in-treatment-of-relapsed-refractory-lymphomas-at-64th-ash-annual-meeting-2\/","url":"https:\/\/myanmarnewsgazette.com\/junshi-biosciences-announces-updated-clinical-data-from-phase-i-study-of-anti-btla-antibody-tifcemalimab-in-treatment-of-relapsed-refractory-lymphomas-at-64th-ash-annual-meeting-2\/","name":"Junshi Biosciences Announces Updated Clinical data from Phase I study of anti-BTLA antibody Tifcemalimab in Treatment of Relapsed\/Refractory Lymphomas at 64th ASH Annual Meeting - Myanmar News Gazette","isPartOf":{"@id":"https:\/\/myanmarnewsgazette.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/myanmarnewsgazette.com\/junshi-biosciences-announces-updated-clinical-data-from-phase-i-study-of-anti-btla-antibody-tifcemalimab-in-treatment-of-relapsed-refractory-lymphomas-at-64th-ash-annual-meeting-2\/#primaryimage"},"image":{"@id":"https:\/\/myanmarnewsgazette.com\/junshi-biosciences-announces-updated-clinical-data-from-phase-i-study-of-anti-btla-antibody-tifcemalimab-in-treatment-of-relapsed-refractory-lymphomas-at-64th-ash-annual-meeting-2\/#primaryimage"},"thumbnailUrl":"https:\/\/ci6.googleusercontent.com\/proxy\/Bse3_g6hNtgUPf1Gv7sPn2rL3xfKl2kuIL4yCLlrgSYQldSibo1k-_IQf8wTG2Fm6Tgm1_iMxetzdWRwSVLSUsa813tF9-RIRbIhb21y2K4eQJ7e342nKKyOYsbD56Ct0kvCmVQL7WRbSeTP7rPLimhpWmFbZ9Hi5usaZxrko1vxlXF55dRuSiRH44TNaA=s0-d-e1-ft#https:\/\/ml.globenewswire.com\/media\/YjYzY2RiOTAtYjViZC00ODEyLWE4ZjktOTBmMzIzODM5N2YxLTEyMDY5Mjg=\/tiny\/Junshi-Biosciences.png","datePublished":"2022-12-11T05:00:24+00:00","dateModified":"2022-12-11T05:00:24+00:00","breadcrumb":{"@id":"https:\/\/myanmarnewsgazette.com\/junshi-biosciences-announces-updated-clinical-data-from-phase-i-study-of-anti-btla-antibody-tifcemalimab-in-treatment-of-relapsed-refractory-lymphomas-at-64th-ash-annual-meeting-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/myanmarnewsgazette.com\/junshi-biosciences-announces-updated-clinical-data-from-phase-i-study-of-anti-btla-antibody-tifcemalimab-in-treatment-of-relapsed-refractory-lymphomas-at-64th-ash-annual-meeting-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/myanmarnewsgazette.com\/junshi-biosciences-announces-updated-clinical-data-from-phase-i-study-of-anti-btla-antibody-tifcemalimab-in-treatment-of-relapsed-refractory-lymphomas-at-64th-ash-annual-meeting-2\/#primaryimage","url":"https:\/\/ci6.googleusercontent.com\/proxy\/Bse3_g6hNtgUPf1Gv7sPn2rL3xfKl2kuIL4yCLlrgSYQldSibo1k-_IQf8wTG2Fm6Tgm1_iMxetzdWRwSVLSUsa813tF9-RIRbIhb21y2K4eQJ7e342nKKyOYsbD56Ct0kvCmVQL7WRbSeTP7rPLimhpWmFbZ9Hi5usaZxrko1vxlXF55dRuSiRH44TNaA=s0-d-e1-ft#https:\/\/ml.globenewswire.com\/media\/YjYzY2RiOTAtYjViZC00ODEyLWE4ZjktOTBmMzIzODM5N2YxLTEyMDY5Mjg=\/tiny\/Junshi-Biosciences.png","contentUrl":"https:\/\/ci6.googleusercontent.com\/proxy\/Bse3_g6hNtgUPf1Gv7sPn2rL3xfKl2kuIL4yCLlrgSYQldSibo1k-_IQf8wTG2Fm6Tgm1_iMxetzdWRwSVLSUsa813tF9-RIRbIhb21y2K4eQJ7e342nKKyOYsbD56Ct0kvCmVQL7WRbSeTP7rPLimhpWmFbZ9Hi5usaZxrko1vxlXF55dRuSiRH44TNaA=s0-d-e1-ft#https:\/\/ml.globenewswire.com\/media\/YjYzY2RiOTAtYjViZC00ODEyLWE4ZjktOTBmMzIzODM5N2YxLTEyMDY5Mjg=\/tiny\/Junshi-Biosciences.png"},{"@type":"BreadcrumbList","@id":"https:\/\/myanmarnewsgazette.com\/junshi-biosciences-announces-updated-clinical-data-from-phase-i-study-of-anti-btla-antibody-tifcemalimab-in-treatment-of-relapsed-refractory-lymphomas-at-64th-ash-annual-meeting-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/myanmarnewsgazette.com\/"},{"@type":"ListItem","position":2,"name":"Junshi Biosciences Announces Updated Clinical data from Phase I study of anti-BTLA antibody Tifcemalimab in Treatment of Relapsed\/Refractory Lymphomas at 64th ASH Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/myanmarnewsgazette.com\/#website","url":"https:\/\/myanmarnewsgazette.com\/","name":"Myanmar News Gazette","description":"","publisher":{"@id":"https:\/\/myanmarnewsgazette.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/myanmarnewsgazette.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/myanmarnewsgazette.com\/#organization","name":"Myanmar News Gazette","url":"https:\/\/myanmarnewsgazette.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/myanmarnewsgazette.com\/#\/schema\/logo\/image\/","url":"https:\/\/myanmarnewsgazette.com\/wp-content\/uploads\/2022\/07\/Myanmar-logo.png","contentUrl":"https:\/\/myanmarnewsgazette.com\/wp-content\/uploads\/2022\/07\/Myanmar-logo.png","width":200,"height":200,"caption":"Myanmar News Gazette"},"image":{"@id":"https:\/\/myanmarnewsgazette.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/myanmarnewsgazette.com\/#\/schema\/person\/c7e2b10e6a2fda5bcbb164cc7b208a0f","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/myanmarnewsgazette.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/ff4aa10d4f36ab9dc3cce9e101792273?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ff4aa10d4f36ab9dc3cce9e101792273?s=96&d=mm&r=g","caption":"admin"},"url":"https:\/\/myanmarnewsgazette.com\/author\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/myanmarnewsgazette.com\/wp-json\/wp\/v2\/posts\/32468"}],"collection":[{"href":"https:\/\/myanmarnewsgazette.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/myanmarnewsgazette.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/myanmarnewsgazette.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/myanmarnewsgazette.com\/wp-json\/wp\/v2\/comments?post=32468"}],"version-history":[{"count":0,"href":"https:\/\/myanmarnewsgazette.com\/wp-json\/wp\/v2\/posts\/32468\/revisions"}],"wp:attachment":[{"href":"https:\/\/myanmarnewsgazette.com\/wp-json\/wp\/v2\/media?parent=32468"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/myanmarnewsgazette.com\/wp-json\/wp\/v2\/categories?post=32468"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/myanmarnewsgazette.com\/wp-json\/wp\/v2\/tags?post=32468"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}